| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print March 21, 2006
Gonda Diabetes Center, Beckman Research Institute of the City of Hope, Duarte, CA 91010
Corresponding Author: rnatarajan{at}coh.org
The Receptor for Advanced Glycation End products (RAGE) and its ligands have been implicated in the activation of oxidant stress and inflammatory pathways in vascular smooth muscle cells (VSMC) leading to the initiation and augmentation of atherosclerosis. Here we report that non-receptor Src tyrosine kinase and the membrane protein Caveolin-1 (Cav-1) play key role in the activation of RAGE by S100B in VSMC. S100B increased the activation of Src kinase and tyrosine phosphorylation of Caveolin-1 in VSMC. A RAGE-specific antibody blocked both these effects. An inhibitor of Src kinase, PP2, significantly blocked S100B induced activation of Src kinase, mitogen activated protein kinases, transcription factors NF-kB and STAT3, superoxide production, tyrosine phosphorylation of Cav-1, VSMC migration, and expression of the pro-inflammatory genes MCP-1 and IL-6. Cholesterol depletion also inhibited S100B-induced effects indicating the requirement for intact caveolae in RAGE specific signaling. Nucleofection of either a Src dominant negative mutant, or a Cav-1 mutant lacking the scaffolding domain, or Cav-1 shRNA significantly reduced S100B induced inflammatory gene expression in VSMC. Furthermore, VSMC derived from insulin resistant and diabetic db/db mice displayed increased RAGE expression, Src activation and migration compared to those from control db/+ mice. The RAGE antibody blocked enhanced migration in db/db cells. These studies demonstrate for the first time that, in VSMC, Src kinase and Cav-1 play important role in RAGE mediated inflammatory gene expression and migration, key events associated with diabetic vascular complications.
J. Biol. Chem, 10.1074/jbc.M511425200
Submitted on October 20, 2005
Revised on March 20, 2006
Accepted on March 21, 2006
Key role of SRC kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Xie, S. Reverdatto, A. Frolov, R. Hoffmann, D. S. Burz, and A. Shekhtman Structural Basis for Pattern Recognition by the Receptor for Advanced Glycation End Products (RAGE) J. Biol. Chem., October 3, 2008; 283(40): 27255 - 27269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, M. A. Reddy, F. Miao, N. Shanmugam, J.-K. Yee, D. Hawkins, B. Ren, and R. Natarajan Role of the Histone H3 Lysine 4 Methyltransferase, SET7/9, in the Regulation of NF-{kappa}B-dependent Inflammatory Genes: RELEVANCE TO DIABETES AND INFLAMMATION J. Biol. Chem., September 26, 2008; 283(39): 26771 - 26781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Reddy, L. M. Villeneuve, M. Wang, L. Lanting, and R. Natarajan Role of the Lysine-Specific Demethylase 1 in the Proinflammatory Phenotype of Vascular Smooth Muscle Cells of Diabetic Mice Circ. Res., September 12, 2008; 103(6): 615 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Omori, T. Ohira, Y. Uchida, S. Ayilavarapu, E. L. Batista Jr., M. Yagi, T. Iwata, H. Liu, H. Hasturk, A. Kantarci, et al. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase J. Leukoc. Biol., July 1, 2008; 84(1): 292 - 301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Villeneuve, M. A. Reddy, L. L. Lanting, M. Wang, L. Meng, and R. Natarajan Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes PNAS, July 1, 2008; 105(26): 9047 - 9052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Leclerc, G. Fritz, M. Weibel, C. W. Heizmann, and A. Galichet S100B and S100A6 Differentially Modulate Cell Survival by Interacting with Distinct RAGE (Receptor for Advanced Glycation End Products) Immunoglobulin Domains J. Biol. Chem., October 26, 2007; 282(43): 31317 - 31331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Herold, B. Moser, Y. Chen, S. Zeng, S. F. Yan, R. Ramasamy, J. Emond, R. Clynes, and A. M. Schmidt Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress J. Leukoc. Biol., August 1, 2007; 82(2): 204 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Raman, P. L. Sappington, R. Yang, R. M. Levy, J. M. Prince, S. Liu, S. K. Watkins, A. M. Schmidt, T. R. Billiar, and M. P. Fink The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock Am J Physiol Gastrointest Liver Physiol, October 1, 2006; 291(4): G556 - G565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-l. Li, M. A. Reddy, Q. Cai, L. Meng, H. Yuan, L. Lanting, and R. Natarajan Enhanced Proatherogenic Responses in Macrophages and Vascular Smooth Muscle Cells Derived From Diabetic db/db Mice Diabetes, September 1, 2006; 55(9): 2611 - 2619. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
